Stopped: The team decided to terminate the trial in order to start a new trial, unrelated to safety reasons
Randomized, double-blind prospective trial to test the efficacy and acceptability of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 480 subject participants and one, 75-90 minute visit.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Salivary Viral RNA Level of SARS-CoV-2
Timeframe: Baseline, 30 minutes
Change in Rapid Antigen Test Salivary Protein Levels of SARS-CoV-2
Timeframe: Baseline, 30 Minutes
Change in Salivary Protein Antigen Levels of SARS-CoV-2
Timeframe: Baseline, 30 minutes